7th September 2022 |4-5 pm (CET) “Non-Interventional Studies: building and broadening the value story”, Daniel Schwarz & Marika Chrápavá, CZ
What is the utility of observational data, and how does it differ from data collected under experimental conditions such as randomized controlled trials (RCTs)? Does it have any other value than optimizing market access in pharma companies? Late-stage clinical research data is not easy to collect and manage but can dramatically improve drug development and clarify the value of new therapies.
Daniel is the Chief Information Officer (CIO) of IBA Ltd. and an associate professor at Masaryk University and the Brno University of Technology. Besides his research in neuroscience, medical image analysis, and machine learning, he also works on data security, data management, and data science in clinical research.
Marika is the Head of the Department of Clinical Projects at IBA Ltd. She has dealt with project management, quality management, and regulatory affairs in the pharmaceutical industry since 2003. In her career, she has led dozens of research projects focusing on medical devices and medicinal products: from basic research and pre-clinical and clinical development to a successful product on the market.
Online via MS Teams, ǀ Please register here! Registration to the webinar is required in advance.
The webinar will be hosted by SPARK at the Faculty of Medicine, Masaryk University, Brno, Czech Republic.
SPARK Europe is the joint network of SPARK sites all over Europe, including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Poland, SPARK Norway, SPARK Tel Aviv, SPARK at Faculty of Medicine, Masaryk University. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence increasing the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since Professor Daria Mochly-Rosen and Kevin Grimes established it in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.